XML 23 R10.htm IDEA: XBRL DOCUMENT
v3.22.2.2

EARNINGS PER SHARE | 9 Months Ended
--- | ---
Sep. 30, 2022
Earnings Per Share [Abstract] |
EARNINGS (LOSS) PER SHARE | EARNINGS PER SHARE The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Amounts attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |
Net income attributable to Quest Diagnostics | $ | 256 |  |  | $ | 505 |  |  | $ | 845 |  |  | $ | 1,605 |
Less: Earnings allocated to participating securities | 2 |  |  | 2 |  |  | 4 |  |  | 6 |
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted | $ | 254 |  |  | $ | 503 |  |  | $ | 841 |  |  | $ | 1,599 |
Weighted average common shares outstanding – basic | 116 |  |  | 123 |  |  | 117 |  |  | 127 |
Effect of dilutive securities: |  |  |  |  |  |  |
Stock options and performance share units | 2 |  |  | 2 |  |  | 2 |  |  | 2 |
Weighted average common shares outstanding – diluted | 118 |  |  | 125 |  |  | 119 |  |  | 129 |
Earnings per share attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |
Basic | $ | 2.20 |  |  | $ | 4.11 |  |  | $ | 7.17 |  |  | $ | 12.63 |
Diluted | $ | 2.17 |  |  | $ | 4.02 |  |  | $ | 7.05 |  |  | $ | 12.41 |
The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Stock options and performance share units | 1 |  |  | — |  |  | — |  |  | — |
The sum of basic and diluted earnings per share attributable to Quest Diagnostics' common stockholders for the first three quarters of 2021 did not equal the total for the nine months ended September 30, 2021 due to both quarterly fluctuations in the Company's earnings and in the weighted average common shares outstanding throughout the period as a result of the impact of share repurchases (see Note 9 for further details regarding the Company's share repurchases).

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration